Payment overview · 2025
General Payments
$2,719.61
145 reported records · 22 companies
Healthcare provider profile · identity verified
Rajesh Bhatnagar, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BRONX, NY · NPI 1386605517
Verified facts
What the public records show
CMS Open Payments records show Rajesh Bhatnagar, M.D. received $2,719.61 in general payments during 2025 across 145 reported records.
Amneal Pharmaceuticals LLC accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gocovri, Nurtec Odt, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rytary by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gocovri by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $377.03 | 13.9% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $373.59 | 13.7% | 19 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $345.69 | 12.7% | 41 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $270.19 | 9.9% | 14 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $164.86 | 6.1% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $152.02 | 5.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $144.47 | 5.3% | 9 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $133.83 | 4.9% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $110.72 | 4.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $94.06 | 3.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $93.03 | 3.4% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $77.73 | 2.9% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $76.09 | 2.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.99 | 2.2% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $58.62 | 2.2% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.43 | 1.3% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.24 | 1.2% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $30.14 | 1.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.96 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.51 | 0.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.28 | 0.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.13 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,701.68 | 144 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17.93 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $461.96 | 49 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $358.85 | 19 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $263.24 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $257.57 | 12 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $152.02 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $133.83 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $110.72 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $94.06 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $93.03 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $83.82 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $83.82 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $77.73 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $76.09 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $60.65 | 5 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $60.65 | 5 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $59.99 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.64 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $48.59 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $35.43 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $33.24 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $9.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gocovri gocovri |
2025 | Gocovri | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 43 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 1492 | 502 |
| Memantine Hcl | Memantine Hcl | 1080 | 340 |
| Gabapentin | Gabapentin | 707 | 302 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 484 | 157 |
| Duloxetine Hcl | Duloxetine Hcl | 314 | 113 |
| Sertraline Hcl | Sertraline Hcl | 275 | 96 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 215 | 69 |
| Divalproex Sodium | Divalproex Sodium | 200 | 68 |
| Levetiracetam | Levetiracetam | 170 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 161 | 40 |
| Primidone | Primidone | 154 | 54 |
| Meclizine Hcl | Meclizine Hcl | 152 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 54 |
| Topiramate | Topiramate | 114 | 36 |
| Nortriptyline Hcl | Nortriptyline Hcl | 103 | 43 |
| Galantamine Hbr | Galantamine Hbr | 79 | 27 |
| Trazodone Hcl | Trazodone Hcl | 79 | 22 |
| Lamotrigine | Lamotrigine | 72 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 29 |
| Mirtazapine | Mirtazapine | 69 | 24 |
| Atorvastatin Calcium | Atorvastatin Calcium | 67 | 30 |
| Amantadine | Amantadine Hcl | 58 | 19 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 57 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 22 |
| Naproxen | Naproxen | 51 | 20 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Rivastigmine | Rivastigmine | 47 | 13 |
| Baclofen | Baclofen | 46 | 20 |
| Rivastigmine | Rivastigmine Tartrate | 46 | 12 |
| Rexulti | Brexpiprazole | 43 | 13 |
| Phenobarbital | Phenobarbital | 38 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 34 | suppressed |
| Carbamazepine | Carbamazepine | 34 | 15 |
| Lacosamide | Lacosamide | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Carbamazepine Er | Carbamazepine | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Eliquis | Apixaban | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Gocovri | Amantadine Hcl | 18 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 18 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Omeprazole | Omeprazole | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 12 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 11 | suppressed |
| Rytary | Carbidopa/Levodopa | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,719.61 · 145 records | Amneal Pharmaceuticals LLC | AMYVID, AUSTEDO XR, BRIUMVI, CREXONT, CUTAQUIG, General - DBS, Gocovri, HYQVIA, JOURNAVX, KESIMPTA, KISUNLA, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONGENTYS, PANZYGA, PONVORY, QULIPTA, QUTENZA, REXULTI, Senza, Symbravo, UBRELVY, UPLIZNA, VRAYLAR, VYEPTI, VYVGART HYTRULO, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gocovri play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error